

Robyn Boerstling

Vice President

Infrastructure, Innovation and Human Resources Policy

August 3, 2017

U.S. Senate
Washington, DC 20510

Dear Senator:

On behalf of the National Association of Manufacturers (NAM), the largest manufacturing association in the United States representing 14,000 manufacturers in every industrial sector and in all 50 states, I am writing to urge you to support H.R. 2430, the Food and Drug Administration Reauthorization Act of 2017 (FDARA), passed by the House of Representatives in July with overwhelming bipartisan support.

Manufacturers appreciate your support of this critical legislation to advance America's innovation leadership in the field of life sciences. The FDARA is the ultimate public-private partnership that supports patients who need life-saving medical treatments while promoting science, research and technological innovation. There are approximately 7,000 medicines currently in development. Consistency, certainty and predictability are required for safe, effective and timely drug reviews.

Manufacturers in the United States drive these breakthroughs and serve as a global leader in a variety of fields, including the pharmaceutical industry. The recently enacted and NAM-supported 21st Century Cures Act will further modernize our approach to the discovery, development, and delivery of medical innovations. The FDARA is necessary and complementary legislation to accelerate new medical breakthroughs. Any delay to the FDARA reauthorization risks future gains in medical discovery and harm to our global standing.

The United States leads the world in the introduction of new medicines. Manufacturers support research pipelines that will lead to further development of treatments and products as well as the creation of more jobs that support innovation and scientific advancement. Therefore we urge you to support H.R. 2430.

Thank you for your consideration.

Sincerely,



Robyn M. Boerstling